Market Overview

UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen


In a report published Friday, Stifel analyst Stephen Willey terminated coverage on Onyx Pharmaceuticals (NASDAQ: ONXX).

In the report, Stifel noted, “We are discontinuing coverage of Onyx Pharmaceuticals due to the company's acquisition by Amgen (AMGN, Covered by our Colleague Joel Sendek, Hold, $115.41) at $125.00 per share in cash. Our last rating on the stock was Hold. Our FY13 estimates for ONXX were EPS of $(2.92) and $626M of revenues.”

Onyx Pharmaceuticals closed on Thursday at $124.70.

Latest Ratings for ONXX

Nov 2013Terminates
Aug 2013DowngradesBuyHold
Aug 2013DowngradesBuyNeutral

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Stephen Willey StifelAnalyst Color Termination Analyst Ratings


Related Articles (ONXX)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Deutsche Bank Downgrades Prudential Financial on Valuation

UPDATE: Stifel Reiterates on Conatus Pharmaceuticals on HCV-POLT Strategy Shift